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ABSTRACT 
Objectives: This study was aimed at determining the effect of folic acid adjunct therapy on homocysteine (HCY) and blood pressure 
(BP) levels in hypertensive subjects.  
Method: The study was a double blind placebo-controlled trial on 100 hypertensive patients randomised into 50 folate and 50 
placebo groups, where the folate group had 5 mg folic acid daily for 8 weeks. Fasting plasma homocysteine, folate and blood 
pressure levels were determined at baseline, at 4 and at 8 weeks. The Mixed Model Repeated Measures analysis of variance was 
applied for data analysis.  
Results: Hyperhomocysteinaemia was found at baseline in the folate (21.3 ± 5.7 µmol/L) and placebo (21.6 ± 4.9 µmol/L) groups 
which did not differ statistically (p > 0.05). Folic acid adjunct therapy, reduced homocysteine levels at 4 weeks by 2.0 µmol/L (9.2 
%, p < 0.05) and at 8 weeks by 1.2 µmol/L (5.6 %, p < 0.05), with no significant (p > 0.05) systolic and diastolic blood pressure 
lowering effect. High base-line folate levels were found in both folate (113.8 ± 51.2 ng/ml) and placebo groups (109.5 ± 51.4 ng/ml) 
with no statistically significant difference (p > 0.05).  
Conclusion: Short-term daily folic acid supplementation over 8 weeks had a significant homocysteine reduction effect with no 
significant reduction in systolic and diastolic blood pressures of hypertensive subjects in Zaria, Nigeria. Hyperhomocysteinaemia 
could not be accounted for by suboptimal folate levels. 
Keywords: Hypertension, Homocysteine, Blood pressure, Folate, Placebo, Nigeria. 
Abbreviations: Hcy, Homocysteine; BP, Blood Pressure; MTHF, MethylTetraHydroFolate; FA/VB9, Folic acid/ Vitamin B9. 
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INTRODUCTION 
Hypertension prevalence is rapidly rising globally and it 
is expected that by the year 2025, 1.56 billion adults will 
be living with hypertension worldwide. 
1, 2 
In some 
African settings, it is rated 40 % 
2
 while surveys in 
Nigeria reveal ranges between 22.5 %-28 %. 
3
 This 
rising trend in Africa has been linked to epidemiologic 
transition, westernisation, and lifestyle changes of 
Africans, such as smoking, alcoholism, obesity, 
sedentary lifestyle, and poor diets high in salt, low in 
fibre, fruits as well as vegetables. 
2
 
These risk factors of hypertension cannot totally explain 
the increased predisposition to hypertensive 
complications like stroke, heart failure or heart attack. 
4
 
Consequently, there are other emerging risk factors, one 
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of which hyperhomocysteinaemia has gained prominent 
focus in the past few decades. 
4
 
Homocysteine is a sulphur containing amino acid, a 
derivative of the metabolism of the essential amino acid, 
methionine obtained from dietary protein like meat, sea 
foods, eggs, and dairy products. 
5
  
Hyperhomocysteinaemia occurs when plasma 
homocysteine level is greater than 15 μmol/L5-6 with 
normal range between 5-15 μmol/L. 7-8 It is metabolised 
via two major pathways:  a remethylation pathway and a 
trans-sulphuration pathway
 9
. Vitamin cofactors such as 
vitamin B12, folic acid, vitamin B6 and betaine are 
required in these metabolic processes. 
7, 9
 Consequently, 
deficiencies in these required cofactors or inherited 
deficiency or mutation in enzymes like cystathionine 
synthase and 5-methyl tetrahydrofolate reductase 
enzyme (MTHFR) necessary for metabolism of 
homocysteine, will lead to increased blood levels of 
homocysteine. 
6-7, 9-10
 Hyperhomocysteinaemia has been 
found to result in widespread endothelial damage that 
manifests clinically with a raised blood pressure. 
11
 
The mechanisms linking hyperhomocysteinaemia and 
high blood pressure are attributed to direct endothelial 
injury on account of the following findings: elevated 
asymmetric dimethylarginine and reactive oxygen 
species; decreased nitric oxide bioavailability and  
generation of peroxynitrite (a strong oxidant that leads 
to nucleic acid and protein oxidation, lipid peroxidation, 
and  inactivation of enzymes which cause necrosis and 
apoptosis of cells). 
9, 12-13 
Furthermore, altered DNA 
methylation, gene expression and smooth muscle 
proliferation, as well as activated transcription factors 
e.g. nuclear factor kappa-β (NFk-β) responsible for 
activation of inflammatory molecules (chemokines, 
cytokines, monocyte chemoattractant protein-1 (MCP-1) 
and interleukins) are also involved. 
9, 12-13
 All these lead 
to endothelial injury, platelet aggregation, thrombi 
formation, smooth muscle proliferation, collagen 
deposition, oxidation of low density lipoprotein 
cholesterol (LDL-C) and damage to elastin fibres 
resulting in atherosclerosis. 
9, 12
  
Studies have shown that hyperhomocysteinaemia is 
prevalent even in normal healthy Nigerians but with few 
studies done in hypertensive Nigerian subjects. 
7, 14-15
 
Hyperhomocysteinaemia has also been attributed to the 
possibility of inadequate dietary folate intake worldwide 
and in sub-Saharan Africa. 
16-18
 It has also been shown 
that simple, inexpensive, non-toxic therapy with 
vitamins B2, B6, B9 (folate) and B12, is therapeutically 
effective at reducing plasma homocysteine levels with 
maximal effect within 2-6 weeks of therapy 
4, 6
. Some 
other study using folic acid alone, showed no significant 
difference (p = 0.48) from using combination of the B 
vitamins
 19
, however with varying degrees of 
homocysteine reduction in the different studies. 
19-20
 The 
effect of folic acid with or without other B vitamins on 
blood pressure has yielded conflicting findings. While 
some studies done elsewhere but not in Nigeria reported 
no blood pressure reduction effect, 
20-22
 another study 
showed systolic (SBP) but not diastolic blood pressure 
(DBP) reduction effect, 
23
 and yet some other study 
showed reduction in both systolic and diastolic blood 
pressures. 
6
 There is a paucity of data regarding the 
effect of folic acid adjunct therapy in hypertensive 
patients in Nigeria, thus noting that there are racial and 
geographic differences worldwide.  The present study 
may become imperative to determine if folic acid can be 
used as an adjunct in the treatment of hypertension in 
Nigerian Africans. 
  The present study was therefore aimed at investigating 
the effect of short-term folic acid supplementation on 
plasma homocysteine and blood pressure levels in 
hypertensive patients in Zaria, Nigeria. Furthermore, it 
was also aimed at determining plasma homocysteine, 
blood pressure and folate levels at base-line, 4 weeks 
and 8 weeks in: hypertensive patients on folic acid 
intervention and hypertensive controls on placebo.  
METHODS 
Research Design and Study Location 
  It was a double-blinded placebo-controlled experimental 
study, which was carried out among Hypertensive 
subjects seen at the Outpatient Department (OPD) of the 
Ahmadu Bello University (ABU) Medical Center, Zaria 
from January, 2016 to June, 2016. Other study locations 
were the Immunology Laboratory and Chemical 
Pathology Laboratory of Ahmadu Bello University 
Teaching Hospital, Zaria where laboratory analysis were 
carried out.  
  Ethical clearance was obtained from the Health Research 
Ethical Committee, Ministry of Health, Kaduna with 
HREC number: MOH/ADM/744/VOL.1/369 and all 
participants gave written informed consent.  
Sampling Technique: A total of 100 patients were 
enrolled prospectively and randomly assigned by block 
randomisation of five to either hypertensive treatment 
(50 patients) and hypertensive placebo (50 patients) 
groups by a trained research assistant (a pharmacist). 
Inclusion and Exclusion Criteria:                                                                           
Inclusion criteria were adult subjects with willingness to 
participate, prior physician diagnosis of hypertension 
(BP ≥ 140/90 mmHg), current use of antihypertensive 
medications and non-diabetics (Fasting blood glucose < 
7 mmol/L). Exclusion criteria were patients with renal 
failure (serum creatinine > 3 g/dl or GFR < 60 ml/min as 
determined by Cockcroft-Gault equation; 
24
 current 
tobacco use; excessive alcohol use and caffeine use; 
chronic folic acid, vitamin B12 and vitamin B6 
supplementation; history of heart failure, stroke, heart 
attack, sickle cell disease or pregnancy; drugs such as 
methotrexate, anticonvulsants, nitrous oxide, 
sulfadoxine-pyrimethamine, penicillamine and failure to 
adhere strictly to protocol or failure to follow up.  
Screening Evaluation: A total of 140 hypertensive 
patients were screened at the Ahmadu Bello University 
Medical Center. There were 34 who did not meet 
eligibility criteria on account of current tobacco use, 
excess alcohol intake, current vitamin supplementation 
and febrile illness on sufadoxine-pyrimethamine 
therapy, diabetes and obesity. The remaining 106 
patients met eligibility criteria, out of which 6 were 
excluded: 2 on account of previous stroke; 2 due to 
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hypertensive heart failure and 2 newly diagnosed 
hypertensive patients not on anti-hypertensive therapy. 
Consequently, there were a total of 100 hypertensive 
patients randomised by blocks of 5 into folic acid 
intervention group and placebo group by a trained 
pharmacist, so that a total of 50 folic acid and 50 
placebo groups were obtained.  
Data Collection: This was done by the lead author and 
4 trained assisting medical doctors via a well-structured 
interviewer-administered questionnaire obtained from 
all screened patients. The most important data obtained 
during the screening included, bio-data (address, age, 
sex, tribe, religion); establishment of hypertension and 
duration of hypertension; drug treatment of 
hypertension; detailed 24 hour dietary recall; family and 
social history. Physical examination, anthropometric 
measurements (weight, height & body mass index in 
kg/m
2
), and blood pressure, were determined at first 
contact (week 0), weeks 4 and 8. Blood sampling for 
plasma homocysteine and folate levels were done on 
weeks 0, 4 and 8.  
Blood Sampling: Blood sample (10 ml) was collected 
from the antecubital vein of either arms, following an 
overnight fast and without tourniquet application. The 
blood was divided into two 5 ml aliquots. This was put 
into labelled potassium EDTA-containing plastic 
lavender vacutainer tubes in which a drop of aprotinin 
(Trasylol
®
) 0.6 TIU/ml or 500 Kallikrein inactivator 
U/ml had been added, as well as plain specimen bottles 
respectively. Aprotinin was to inhibit the activity of 
proteinases and enhance stability of homocysteine or 
folate in plasma. The test tubes were taken to the 
Immunology laboratory of ABUTH, Zaria within 4 
hours of collection in ice cubes, where they were 
centrifuged at 1800 rpm for 20 minutes. The plasma was 
separated within one to two hours and divided into 
aliquots in cryovials and stored at -70 ºC until assay. 
Baseline investigations such as serum electrolyte, urea 
and creatinine and fasting blood glucose, were also 
assayed in the Chemical Pathology Laboratory of the 
ABUTH, Zaria using the Chenray 120 automated 
clinical chemistry auto-analyser.  
Measurement of Plasma Homocysteine and Folate 
Levels: Laboratory analysis was by laboratory scientist 
in 2 batches under the same prevailing condition of 
storage and in the presence of the lead author. The 
Human direct homocysteine enzyme linked 
immunosorbent assay kit (ELISA-Elabscience 
Biotechnology Co., Ltd., WuHan, P.R.C. with Lot No: 
AK0016JULI5066 and Catalog No: E-EL-HO156), was 
used for in-vitro quantitative determination of human 
homocysteine in plasma with detection range of 0.63-40 
pmol/mL equivalent to 0.63-40 µmol/L and based on 
manufacturer’s manual and according to the ELISA 
technique described by Frantzen et al. 
25
 The folic acid 
ELISA kit (Elabscience Biotechnology Co. Ltd., 
WuHan, P.R.C. with Lot No: AK0016JULI5067 and 
Catalog No: E-EL-0009), was used for the in-vitro 
quantitative determination of plasma folate levels, with 
detection range of 12.5-800 ng/mL. 
Treatment and Concomitant treatment: Those in the 
folate group were given a 4 week supply of pills and 
instructions on pill-taking, daily 5 mg folic acid while, 
those in the placebo group were given same supply of its 
matching placebo, which looked similar to folic acid in 
shape, smell and size but were devoid of the folic acid 
active ingredient. Participants remained on the same 
daily dose throughout the entire study for 8 weeks in 
addition to their standard anti-hypertensive therapy 
(calcium channel blockers, ACE inhibitors, Angiotensin 
II receptor blockers, diuretics and beta-blockers as the 
case may be). The patients, physicians, and all members 
of the research team as well as the lead author except the 
pharmacist, were all blinded to the randomisation 
procedure and treatment assignments from the 
beginning till the end of the study. Patients were 
encouraged to return to the hospital for follow up visits 
every 4 weeks. Participant compliance to therapy was 
also measured by pill count. Blood folate levels were 
determined as a marker of folic acid intake. Extensive 
health talks were given to the subjects on drug 
compliance and lifestyle modification by the lead 
author, the nurses and pharmacist. Provision was made 
ahead of time to locate patients at home if they did not 
attend clinic as scheduled and two weekly reminders on 
pill compliance were sent to each subject by text 
messages on their mobile telephones. Patients who 
failed to appear on weeks 4 and 8 of the treatment, 
despite all attempts to locate them were withdrawn from 
the study. 
Data Analysis: Data was validated and analysed by 
SPSS version-16 software (SPSS, Inc., Chicago, IL, 
USA). Data was presented as mean ± SD for parametric 
data. Difference between the 2 groups was determined 
by Chi square analysis for non-numerical variables and 
student’s t - test for numerical variables. Mixed model 
repeated measures analysis of variance (ANOVA) with 
post-hoc Bonferroni and Parameter estimates was used 
to compare folate, homocysteine and blood pressure 
levels in intervention and placebo groups at week 0, 4 
and 8. Partition limit for homocysteine was 15 µmol/L 
and that for folate was 20 ng/mL. Level of significance 
was assumed to be p < 0.05 at 95 % confidence interval.  
RESULTS 
Group Profile: Out of the 100 hypertensive patients 
that were enrolled, 14 were withdrawn prior to 
completion of the study. There were 12 patients who 
were lost to follow up by week 4; 7 in the intervention 
group and 5 in the placebo group while 2 patients 
withdrew their consent from the placebo group by week 
8 (Figure 1). The remaining 86 hypertensive patients 
consisted of 43 subjects in each group that completed 
the study (Figure 1).  
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Socio-Demographic Findings: The baseline socio-
demographic data were not significantly different 
between the folic acid and placebo groups with respect 
to the age, sex, tribe, and educational status (p> 0.05) 
(Table 1).  The mean age of the folic acid group was 
50.4 ± 10.2 years, similar to that of the placebo group 
(51.0 ± 9.4 years) (p = 0.97).  There were 28 (65.1 %) 
females in the folic acid group (p = 0.65), similar to the 
placebo group, 29 (67.4 %). There was also no 
significant difference (p = 0.65) in the number of males 
in both the folic acid (15, 34.9 %) and placebo groups 
(14, 32.6 %) respectively (Table 1). 
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Clinical and Laboratory Findings: The baseline 
clinical and laboratory parameters of the study subjects 
did not differ significantly (p> 0.05) (Table 2). The mean 
± SD systolic blood pressure in the folic acid group was 
144.70 ± 20.7 mmHg which did not differ statistically (p 
= 0.57), from  that of the placebo group (142.3 ± 18.1 
mmHg). The mean ± SD diastolic blood pressure of the 
folic acid group was 89.1 ± 11.5 mmHg with no 
statistically significant difference (p = 0.60), with that of 
the placebo group (90.5 ± 12.9 mmHg). The Body mass 
index, vegetables and fruits in daily diet, duration of 
hypertension, family history of hypertension and anti-
hypertensive drug therapy between the two groups also 
did not differ significantly (p > 0.05) (Table 2).  
The base-line folate (p = 0.86) and homocysteine 
concentrations (p = 0.81) were not significantly different 
between the two groups (p > 0.05) (Table 2). The base-
line mean homocysteine levels in both folic acid (21.3 ± 
5.7 µmol/L) and placebo (21.6 ± 4.9 µmol/L) groups 
were found to be higher than normal (15 µmol/L). The 
base-line mean folate levels were also high in both the 
folic acid (112.5 ± 52.1 ng/mL) and placebo (110.6 ± 
51.2 ng/mL) groups (20 ng/mL). The Glomerular 
filtration rate (GFR), packed cell volume (PCV) and 
fasting blood glucose (FBG) were within normal limits in 
both groups and had no statistically significant difference 
(p > 0.05) (Table 2). 
  
 
 
Plasma Folate Levels: The mean plasma folate levels 
in the intervention group at weeks 0, 4 and 8 were, 
113.8 ± 51.2 ng/ml, 144.3 ± 50.7 ng/ml and 160.7 ± 65.2 
ng/ml respectively while those of the placebo group 
were 109.5 ± 51.4 ng/ml, 141.0 ± 50.1 ng/ml and 142.7 
± 73.9 ng/ml, respectively (Figure 2). There was a 
statistically significant (p < 0.001), difference in 
timelines between weeks 0 and 4 with regards to plasma 
folate concentrations as well as weeks 0 and 8 (Figure 
2). 
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Figure 2:  Plasma Folate Levels Between Folate and Placebo Groups over 8 Weeks (n = 43) 
Mixed model repeated measures ANOVA with post-hoc Bonferroni. *Mean difference between Folic acid and Placebo 
groups at week 0 and 4 as well as week 0 and 8, significant at p < 0.001. 
 
Plasma Homocysteine Levels: The mean plasma 
homocysteine levels in the folic acid group at weeks 0, 4 
and 8 were as in Table 3. There was a statistically 
significant (p = 0.005), difference in mean plasma 
homocysteine levels in the folic acid group when 
compared to the placebo group between weeks 0 and 4 
as well as weeks 0 and 8 by mixed model repeated 
measures ANOVA with post-hoc Bonferroni test (Table 
3). 
Blood Pressures Levels: Similarly, there was a 
significant difference in systolic (p=0.007) and diastolic 
(p< 0.001) blood pressures in the folic acid group when 
compared to the placebo group between weeks 0 and 4 
as well as weeks 0 and 8 respectively (Table 3). 
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Effect of 8 weeks Folic Acid Supplementation on 
Plasma Homocysteine and Blood Pressure Levels 
between Folic Acid and Placebo Groups  
Plasma Homocysteine Levels: Mixed model repeated 
measure analysis of variance (ANOVA) with parameter 
estimates was used to determine the effect of 5 mg folic 
acid supplementation on plasma homocysteine levels at 
weeks 4 and 8.  The between-subjects effect showed that 
the folic acid group had a statistically significant 
decrease in plasma homocysteine at week 4 (b = -2.0, p 
= 0.03) and week 8 (b = -1.2, p = 0.02) from base-line 
values (Table 4). Hence plasma homocysteine levels 
reduced by 2 µmol/L (9.4 %) from base-line values by 
week 4 and 1.2 µmol/L (5.9 %) from base-line values by 
week 8. 
Systolic Blood Pressure Levels (SBP): Between-
subjects effects showed that folic acid supplementation 
had no statistically significant (p > 0.05) decrease in 
SBP at week 4 and week 8 with a decrease of 5.7 mmHg 
(3.3 %) and 2.3 mmHg (1.9 %) respectively (Table 4). 
Diastolic blood pressure (DBP): The DBP at 4 and 8 
weeks was compared with base-line values to detect 
between-subjects effects. A decrease of 3.1 mmHg (3.6 
%) by week 4 and 1.5 mmHg (1.8 %) by week 8 were 
observed but these were not statistically significant (p > 
0.05) (Table 4) 
 
 
 
DISCUSSION 
Studies are on-going in different parts of the world to 
determine the role of plasma homocysteine and whether 
its reduction would help ameliorate the incidence and 
complications of cardiovascular diseases. 
6
 In view of 
this, we have attempted in this randomised double blind 
placebo controlled study, to investigate whether folic 
acid supplementation as an adjunct therapy, would have 
any lowering effect on homocysteine and blood pressure 
levels in hypertensive patients in Zaria, Nigeria. 
The mean ages of the subjects were within the 5
th
 
decade similar to previous studies. 
6, 20, 27
 It however, 
contrasts reports of other studies 
21, 22, 28
 which involved 
older adults ≥ 65 years, as well as the Tehran 
homocysteine survey 
23
, which involved younger adults 
(mean, 41 ± 2 years). The current study had a female 
preponderance, perhaps due to the health seeking nature 
of females, similar to the Tehran homocysteine study. 
23
 
Moreso, there appears to be a gender shift in the global 
trend of cardiovascular diseases towards females. 
29
 
Females have also been shown to be predisposed to pre-
eclampsia and hypertension, due to molecular vascular 
risk factors like soluble endoglins, tyrosine kinase, 
vascular endothelial growth factor (VEGF) implicated in 
its causation. 
30
 
The mean plasma folate levels in the folic acid and 
placebo groups, were 5 times higher than the upper limit 
of normal (2-20 ng/mL or 4.5-45.3 nmol/L) using the 
standard reference range for the United States. 
31
 This 
contrasts reports from the United States and European 
countries where folate levels were reported to range 
from 9.8-21 nmol/L with median pre-treatment value of 
14.2 nmol/L as reported by the meta-analysis of 25 
randomised controlled trials. 
20
 Moreso, there has been 
reports of folate deficiency outside Nigeria 
18
 with 
reference range for Europe being between 3.8-16.0 
ng/mL and USA between 8.4-35.2 ng/mL, while that for 
Uganda was 4.17-20 ng/ml. 
32
 Research indicates that 
folate deficiency may be an important cause of 
hyperhomocysteinaemia in the general population. 
19, 27
 
However, the current study is interesting because it 
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shows a contrary result and will guide the non-
communicable disease control efforts in the country not 
only in determining the real operative risk factors but 
also to prescribe remedies appropriate to our setting as 
this study has shown that folate was not deficient.  
The high pre-treatment folate levels in our subjects may 
be attributed firstly to the difference in racial factors 
which are yet undefined as well as geographical factors 
especially as the substantial number of hypertensive 
subjects in both folic acid and placebo groups had 
vegetables and fruits in their daily diet as vegetables are 
common in this farming environment. Secondly, the 
dietary pattern of the inhabitants of the Northern region 
of Nigeria, where their diet contains rich sources of 
folate and vitamins obtained from vegetables such as 
spinach, lettuce, pumpkin, okra, green leafy vegetables, 
cucumber, carrots and fruits like watermelon which are 
currently grown extensively in the North and marketed 
down to the Southern States 
33-34
. The Hausas also eat 
grains, beans, peanuts also in form of “kuli kuli”, and 
milk (in form of “fura da nono”) as complementary 
protein diet which are also rich sources of vitamins and 
folate. 
33-34
  
Hyperhomocysteinaemia is defined as total 
homocysteine ≥ 15 µmol/L with levels of 16-30 µmol/L 
classified as mild, 31-100 µmol/L as moderate and > 
100 µmol/L as severe hyperhomocysteinaemia. 
6
 This 
study showed high pre-treatment homocysteine levels in 
hypertensive patients in both groups. This is similar to 
reports from other parts of Nigeria 
7, 13, 15
 Reports from 
other countries like Iran, 
23
 India
 6
 and Italy 
27
 showed 
similar high levels. However, this is contrary to reports 
from the meta-analysis of 25 randomised controlled 
trials done in USA and European countries, which 
showed median pre-treatment homocysteine levels of 
10.5 µmol/L (8.5-13.6 µmol/L). 
20
 The disparity 
between the current study and that of the USA and 
European countries may be attributed to racial, ethnic 
and geographical differences. For instance, studies have 
shown that there are two types of 
hyperhomocysteinaemia: firstly, that due to major 
genetic mutations of the enzymes implicated in 
homocysteine metabolism such as cystathionine-beta-
synthase (CBS), methylenetetrahydrofolate reductase 
(MTHFR), or due to enzymes involved in methyl-B12 
synthesis and homocysteine methylation. 
35-36
 The latter 
which is rare, accounts for the severe form of 
hyperhomocysteinaemia. 
35-36
  
Secondly, hyperhomocysteinaemia due to socio-
environmental factors like folate, vitamin B6 and B12 
deficiencies or genetic factors like thermolabile MTHFR 
deficiency. The deficiencies in the socio-environmental 
factors are the more common forms which cause mild to 
moderately elevated homocysteine levels as observed in 
this study 
35-36
 The base-line hyperhomocysteinaemia 
may however, not be accounted for by suboptimal folate 
status, since the folate levels obtained in the present 
study were well above the reference range for healthy 
adults in the United States. The plasma vitamin B12 and 
B6 levels were not determined in the present study hence 
their deficiencies could not be ascertained as the cause 
of the high homocysteine levels observed. However, it is 
pertinent to note that a study by Flemming et al. 
39
 
showed that vitamin B12 deficiency was rare in Northern 
Nigerians. 
Furthermore, due to lack of facilities for genetic studies 
in Nigeria, knowledge on genetic aberrations and their 
polymorphisms are not known, 
7
 hence the mild to 
moderate hyperhomocysteinaemia seen in almost all the 
86 subjects in this study cannot be accounted for by 
genetic polymorphism as proposed in a study done in 
Gombe town of Nigeria, 
14
 as this was not assayed in 
this study.  
Poor dietary intake of vitamin containing foods was 
proposed to occur in Nigerians from the Northern part of 
the country as reported in a study by Vanderjagt in 
2000. 
17
 That study concluded that the adolescent girls in 
the North were at greater risk of vitamin B12 deficiency 
than folate deficiency, consistent with the fact that their 
diet was proposed then to have few foods that contained 
vitamin B12. That study however, may not generalize for 
adult population, as young adolescents were studied and 
perhaps study of current young adolescents need to be 
carried out. 
17
  
Other factors that affect homocysteine levels are alcohol 
use and smoking. 
9
 There was no history of smoking or 
alcohol intake in any of the subjects in the current study 
that could have contributed to hyperhomocysteinaemia. 
Smoking and alcohol consumption have been found to 
be associated with hyperhomocysteinaemia 
6, 40-41
. The 
effect of nicotine and or carbon monoxide (CO) from 
smoking can suppress vitamin B6, B12 and folate levels. 
6, 40-41
 The renal statuses of all the subjects were within 
normal as determined by the GFR 
24
 hence cannot 
account for the high base-line homocysteine levels, as 
impaired renal status has been shown to be associated 
with hyperhomocysteinaemia. 
9, 42
 
There was evidence of folate intake by the folic acid 
intervention group as plasma folate levels rose from pre-
treatment levels by weeks 4 and 8. There was a 
statistically significant (p < 0.001), difference in time-
lines between the folic acid intervention group and the 
placebo group. The initial rise in folate levels in the 
placebo group despite the absence of intake of folic acid 
is similar to what was obtained in the Tehran 
homocysteine survey. 
23
 This remains unclear, but may 
be attributed to a “placebo effect” or an improvement in 
lifestyle and dietary modification with increased folate 
consumption in their diet from fruits and vegetables, as 
folate appears to be the most important dietary 
determinant of plasma homocysteine. 
23
 This dietary 
modification can be attributed to the extensive health 
talks given to the hypertensive patients at their base-line 
visit. 
Following supplementation with daily dose of folic acid 
(5 mg) over a period of 8 weeks in the current study, 
there was a 9.4 % reduction (2 µmol/L) in plasma 
homocysteine levels by the 4
th
 week and 5.9 % 
reduction (1.2 µmol/L) by the 8
th
 week. This was 
consistent with previous reports, but with varying 
degrees of reduction 
6
. In typical European countries and 
USA, 0.5-5 mg folic acid daily supplementation was 
shown to reduce homocysteine levels by a quarter to a 
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third (25 %) 
20, 43
 One other study showed a 49.9 % 
reduction of homocysteine levels with vitamin cofactor 
combination, which was not statistically different from 
the results of using folic acid alone. 
19
 The reason for the 
marginal reduction found in the present study may be 
attributed to the high pre-treatment folate levels. 
Research has shown that absolute reductions in blood 
homocysteine concentrations with folic acid 
supplementation are greater at higher pre-treatment 
blood homocysteine concentrations and lower pre-
treatment folate concentrations. 
20, 44
 This was not the 
case with the present study were both the pre-treatment 
folate and homocysteine levels were very high even at 
base-line. 
The present study also revealed non-significant 
reduction of folic acid adjunct therapy of systolic and 
diastolic blood pressures after 8 weeks. This was similar 
to the findings of McMahon et al. 
21
 and the vitamin 
intervention for stroke prevention (VISP) trial, 
22
 in 
which folate supplementation, had no effect on both 
systolic and diastolic blood pressure. The findings of the 
present study contrasts reports from the meta-analysis of 
25 randomised controlled trials in USA and European 
countries, involving the use of folic acid with or without 
other B vitamins for a short duration of 2 to 14 weeks.
 20
 
The National Health and Nutrition Examination Survey 
(NHANES) study done in the US showed that a one 
standard deviation increase in red blood cell folate (100 
ng/ml) was associated with a 5 mmHg reduction in both 
diastolic and systolic blood pressures. 
45
 It also contrasts 
reports of the Tehran homocysteine survey, 
23
 in which 
supplementation for 8 weeks significantly (p < 0.001), 
reduced SBP with no significant reduction in DBP. The 
reason for the disparity in the findings of this study and 
others may probably be because base-line homocysteine 
levels were only reduced marginally. In addition, folic 
acid was not combined with other B vitamins or 
therapies like betaine (trimethylglycine) or thiols in the 
present study which may possibly further explain the 
non-reduction of blood pressure and marginal 
homocysteine reduction effect.   
CONCLUSION 
In conclusion, the study showed that daily folic acid 
supplementation of standard anti-hypertensive therapy 
over 8 weeks, had a significant homocysteine reduction 
effect with no statistically significant reduction in 
systolic and diastolic blood pressures in hypertensive 
subjects in Zaria, Nigeria. Hyperhomocysteinaemia 
found in the subjects could not be accounted for by 
suboptimal folate levels as base-line pre-treatment 
plasma folate levels were high in both hypertensive folic 
acid and placebo groups.  
RECOMMENDATIONS 
Folate adjunct therapy is not recommended in adult 
Nigerian hypertensives as a bid to control blood 
pressure except in Nigerian pregnant women and sickle 
cell disease patients as recommended by the expert 
committee of Non Communicable Diseases; rather 
emphasis should be on anti-hypertensive drug adherence 
and lifestyle modification. Sampling multiple centres 
across Nigeria and the young and elderly should be 
carried out to determine whether homocysteine is a risk 
factor for hypertension and whether folic acid 
supplementation will produce similar outcome as in this 
study. Further longitudinal studies should be carried out 
using combination therapy of folic acid with other B-
vitamins, betaine or thiols to determine whether there 
will be more reduction effect on homocysteine as well 
as any blood pressure effect. Genetic studies should be 
undertaken to determine if there is any genetic mutation 
in the gene encoding 5, 10-methylene tetrahydrofolate 
reductase (MTHFR) required for homocysteine 
metabolism in hypertensive Nigerians. 
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